FOLH1 and prostate carcinoma: Carl’s team overexpressed a dominant-negative mutant of the TGF-β R II gene in CAR-T cells targeting PSMA, which significantly enhanced the ability of CAR-T cells to infiltrate, proliferate, and mediate antitumor responses in a prostate cancer model by inhibiting the TGF-β signaling pathway within tumors [70].